BRCA2 and ovarian cancer: We have analyzed pathogenic variant detection rates in 6 actionable high penetrance genes recommended by NCCN (see text footnote 2: BRCA1, BRCA2, PALB2, TP53, PTEN, and CDH1) in patients with breast and/or ovarian cancer, categorized in sub-groups based on specific clinical presentation (Table 3).